BMY (Bristol Myers Squibb) מחיר לרווח עתידי

Bristol-Myers Squibb (BMY) dominates the biopharmaceutical sector thanks to patents on key oncology drugs. The company's forward P/E ratio demonstrates the current valuation of the business relative to earnings, while 9.40 reflects the most recent value of this metric. Portfolio growth is driven by partnerships with innovative startups, and the optimization of outsourced manufacturing aims to increase the final margins of drug production.
פילוחים אנליטיים ודוחות נתונים של חברת bms.com (BMY)

Bristol-Myers Squibb (BMY) revenues depend on the patent protection of key drugs and the success of new molecules. This ratio compares the current share price with the expected future earnings per share. The metric determines the degree of overpayment for projected cash flow amid inflationary pressures. Rising values signal inflated expectations coupled with the risk of losing drug exclusivity. By analyzing the company's forward P/E ratio, an investor assesses the sustainability of the business valuation.